Get an alert when ALLUCENT (UK) LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-11-27 (in 6mo)

Last made up 2025-11-13

Watchouts

None on the register

Cash

£841K

+40.7% vs 2023

Net assets

£2M

-50.5% vs 2023

Employees

81

+44.6% vs 2023

Profit before tax

-£2M

+19.3% vs 2023

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £15,877,737£15,324,563
Operating profit -£2,218,075-£1,793,860
Profit before tax -£2,221,585-£1,793,862
Net profit -£2,224,796-£1,796,957
Cash £597,934£841,448
Total assets less current liabilities £3,560,530£1,763,573
Net assets £3,560,530£1,763,573
Equity £3,560,530£1,763,573
Average employees 5681
Wages £5,486,339£6,220,341
Directors' remuneration

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin -14.0%-11.7%
Net margin -14.0%-11.7%
Return on capital employed -62.3%-101.7%
Current ratio 1.19x1.06x
Interest cover -631.93x-896930.00x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Name history

Renamed 1 time since incorporation

  1. ALLUCENT (UK) LIMITED 2023-02-20 → present
  2. PHARM-OLAM INTERNATIONAL (UK) LIMITED 1995-11-14 → 2023-02-20

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Abridged
Yes — abridged accounts (limited disclosure)
Auditor
UHY Hacker Young LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The financial statements of the company have been prepared on a going concern basis, which the directors believe to be appropriate. New Pharm-Olam Holdings LLC, the ultimate parent company, has confirmed its intention to support the company, as required, to ensure that the company can meet its obligations for a period of at least one year from the date of issuance of these financial statements.”

Group structure

  1. ALLUCENT (UK) LIMITED · parent
    1. Allucent (Belgium) BVBA 99% · Belgium · management and consulting of clinical research trials
    2. Allucent (IT) S.R.L. 100% · Italy · management and consulting of clinical research trials
    3. Allucent (FR) SAS 100% · France · management and consulting of clinical research trials
    4. Allucent (ES) SL 100% · Spain · management and consulting of clinical research trials
    5. Allucent (PL) (Polska) Sp z.o.o. 100% · Poland · management and consulting of clinical research trials
    6. Allucent DOO Beograd 100% · Serbia · management and consulting of clinical research trials
    7. Allucent(CZ) s.r.o. 100% · Czech Republic · management and consulting of clinical research trials
    8. Allucent (India) Pvt. Ltd 100% · India · management and consulting of clinical research trials
    9. Allucent Klinik Arastirma Ve Deney Ticaret Limited Sirketi 100% · Turkey · management and consulting of clinical research trials
    10. Allucent (HU) Kft 100% · Hungary · management and consulting of clinical research trials
    11. Allucent(HR) d.o.o. 100% · Croatia · management and consulting of clinical research trials
    12. Allucent Research Israel Ltd 100% · Israel · management and consulting of clinical research trials
    13. Pharm-Olam (Bulgaria) EOOD 100% · Bulgaria · dormant

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 15 resigned

Name Role Appointed Born Nationality
BRAND, Howard Secretary 2025-11-12
BRAND, Howard Director 2025-01-08 Apr 1972 American
STAFFORD, Paula Brown Director 2025-01-08 May 1964 American
Show 15 resigned officers
Name Role Appointed Resigned
BRENNAN, Chris Secretary 2021-12-16 2025-11-12
MUNK, Susan Secretary 1995-11-14 2017-11-20
AGROSKIN, Daniel Director 2021-12-16 2025-01-08
BARRY, John David Director 2017-11-20 2020-03-27
BRENNAN, Christopher Director 2025-01-08 2025-11-12
DAVIE, Robert James Director 2020-03-27 2021-12-16
GASSEN, Natalie Kay Director 2017-11-20 2022-08-01
GOLDBERG, Mark Alan Director 2021-12-16 2025-01-08
GRANGE, David Lawrence Director 2017-11-20 2020-03-27
KHAN, Yamin Director 2017-11-20 2019-07-26
MUNK, Susan Director 1997-02-12 2017-11-20
MUNK, Zev Moshe Director 1995-11-14 2017-11-20
NATORFF, Benona Lillian, Dr Director 1997-02-12 2000-10-23
SHIMOTA, Richard William Director 2021-12-16 2025-01-08
STROTHMAN, Peter Maurice Director 2021-12-16 2025-01-08

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Dr Zev Moshe Munk Individual Significant influence 2016-04-06 Ceased 2020-06-19
Allucent (Uk) Group Limited Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Active

Filing timeline

Last 20 of 115 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2023-02-20 CERTNM Certificate change of name company PDF
Date Type Category Description
2025-12-09 AA accounts Accounts with accounts type full PDF
2025-11-13 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-11-13 TM01 officers Termination director company with name termination date PDF
2025-11-13 TM02 officers Termination secretary company with name termination date PDF
2025-11-13 AP03 officers Appoint person secretary company with name date PDF
2025-01-09 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-01-09 TM01 officers Termination director company with name termination date PDF
2025-01-09 AP01 officers Appoint person director company with name date PDF
2025-01-09 AP01 officers Appoint person director company with name date PDF
2025-01-09 AP01 officers Appoint person director company with name date PDF
2025-01-09 TM01 officers Termination director company with name termination date PDF
2025-01-09 TM01 officers Termination director company with name termination date PDF
2025-01-09 TM01 officers Termination director company with name termination date PDF
2025-01-06 AA accounts Accounts with accounts type medium
2024-01-06 AA accounts Accounts with accounts type medium
2023-12-07 CS01 confirmation-statement Confirmation statement with updates PDF
2023-12-07 PSC05 persons-with-significant-control Change to a person with significant control PDF
2023-12-06 PSC05 persons-with-significant-control Change to a person with significant control PDF
2023-12-05 PSC05 persons-with-significant-control Change to a person with significant control PDF
2023-02-20 CERTNM change-of-name Certificate change of name company PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
5

last 12 months

Capital events
0

last 24 months

Officers appointed
1

last 12 months

Officers resigned
2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page